SCHEMBL1522452

SCHEMBL1522452

C=CCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2cccnc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.57
MAPK1 P28482 1/20 0.57
CYP2C9 P11712 3/20 0.50
NR1I2 O75469 1/20 0.50
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
GAA P10253 2/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1522455 0.91 HSD17B10 (0.46) HSD17B10MAPK1CYP2C9NR1I2MEN1
SCHEMBL1377316 0.86 MAPK1 (0.56) HSD17B10MAPK1CYP2C9NR1I2CA12
SCHEMBL1376802 0.86 MAPK1 (0.58) HSD17B10MAPK1CYP2C9NR1I2TDP1
SCHEMBL1522473 0.86 MAPK1 (0.58) HSD17B10MAPK1CYP2C9NR1I2MEN1
SCHEMBL1522399 0.86 MAPK1 (0.58) HSD17B10MAPK1CYP2C9NR1I2MEN1
SCHEMBL1522654 0.85 MAPK1 (0.57) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL1522465 0.85 MAPK1 (0.62) HSD17B10MAPK1CYP2C9NR1I2MEN1
SCHEMBL1522497 0.85 MAPK1 (0.57) HSD17B10MAPK1CYP2C9NR1I2KDM4E
SCHEMBL1522331 0.84 CYP2C9 (0.58) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL1522694 0.84 MAPK1 (0.56) HSD17B10MAPK1CYP2C9NR1I2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040162285-A1 Anti-infective agents ABBOTT LABORATORIES 2004-08-19 US claimed
US-20040097492-A1 Anti-infective agents ABBOTT LABORATORIES 2004-05-20 US claimed
US-20040087577-A1 Anti-infective agents ABBOTT LABORATORIES 2004-05-06 US claimed
EP-2361913-A1 Anti-infective agents Abbott Laboratories (US) 2011-08-31 EP disclosed
US-7902203-B2 Anti-infective agents ABBOTT LABORATORIES, INC. (US) 2011-03-08 US disclosed
EP-1560827-B1 ANTI-INFECTIVE AGENTS ABBOTT LAB (US) 2010-12-29 EP disclosed
US-20050075331-A1 Anti-infective agents ABBOTT LABORATORIES 2005-04-07 US disclosed
US-20040167123-A1 Anti-infective agents ABBVIE INC. 2004-08-26 US disclosed
US-20040162285-A1 Anti-infective agents ABBOTT LABORATORIES 2004-08-19 US disclosed
US-20040097492-A1 Anti-infective agents ABBOTT LABORATORIES 2004-05-20 US disclosed
US-20040087577-A1 Anti-infective agents ABBOTT LABORATORIES 2004-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097492-A1 Anti-infective agents POLR1C, RPL5, POLB HSD17B10 1232/4885MAPK1 1456/4885CYP2C9 682/4885
US-20040162285-A1 Anti-infective agents POLR1C, RPL5, POLB HSD17B10 1232/4885MAPK1 1456/4885CYP2C9 682/4885
US-20040167123-A1 Anti-infective agents SERPINB1, CYP51A1, ZC3HAV1 HSD17B10 1422/4885MAPK1 739/4885CYP2C9 1503/4885
US-20050075331-A1 Anti-infective agents RPL35, POLI, POLRMT HSD17B10 1335/4885MAPK1 2328/4885CYP2C9 1715/4885
US-20040087577-A1 Anti-infective agents POLR1C, RPL5, POLB HSD17B10 1232/4885MAPK1 1456/4885CYP2C9 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.